Abstract
The quality of the graft is thought to be essential for a good outcome in aulologuus stem cell transplant for CML. We have recently demonstrated that a) Ph-negative peripheral blood progenitor cells (PBPC) can be collected by leukapheresis during early recovery after chemotherapy-induced marrow aplasia, b) these cells are able to restore nORnal polyclonal hemopoiesis after autografting and c) the best clinical results are achieved in patients autografted with Ph-negative PBPC In order to monitor minimal residual disease in Ph-negative PBPC, we set a quantitative-competitive RT-PCR assay for BCR-ABL and analyzed Ph-negative collections in 18 patients mobilized in the first year from diagnosis without previous IFN-a treatment. We generated a construct m which the fusion region of the BCR-ABL gene was cloned in pCR-II vector and a 222 bp of foreign DNA was inserted in the ABL portion of the cDNA. This construct was used as competitor DNA to estimate BCR-ABL and ABL transcripts in 147 samples Ratio between the t\u> BCR-ABL and ABL was calculated for every sample. Statistical correlation between cytogenetics and QC-RT-PCR was higher than 0.8. Ph-negative collection from the same patients showed more than one log of difference in the amount of BCR-ABL transcripts, with the lower levels in the first two teukaphereses Sample BCR-ABL trans/ugRNA (median) BCR-ABL/ABL diagnosis 50000 0.3 1st leuk. 100 0.002 2nd leuk. 100 0.002 3rd leuk. 500 0.006 4th leuk 500 0.01 Sthleuk 1500 0.01 Indeed, the BCR-ABL level found in the first leukaphereses of these patients was lower than in the corresponding samples from a group of patients pre-treated for more than 12 months with IFN-α therapy. Patients mob BCR-ABL Irans/BCR-ABL/ABL agRNA fmedl in the 1 st leuk. (med) £12 mo. fromdx.inoINF 100 0.002 >12mo.IFN 1000 0.01 In conclusion, quantitative-competitive RT-PCR for BCR-ABL has been proven to be a powerful tool in monitoring leukemic contamination in PBPC collections. Follow-up data of patients autografted with low-contamination PBPCs are necessary to establish the clinical relevance of this selection.
| Original language | English |
|---|---|
| Pages (from-to) | 758 |
| Number of pages | 1 |
| Journal | Experimental Hematology |
| Volume | 26 |
| Issue number | 8 |
| Publication status | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Cell Biology
- Genetics
- Hematology
- Oncology
- Transplantation
Cite this
Quantification of BCR-ABL transcripts by QC-RT-PCR in leukapheresis-collected blood progenitor cells in early diagnosed patients with CML. / Corsetti, M. T.; Frassoni, F.; Vassallo, F.
In: Experimental Hematology, Vol. 26, No. 8, 1998, p. 758.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Quantification of BCR-ABL transcripts by QC-RT-PCR in leukapheresis-collected blood progenitor cells in early diagnosed patients with CML
AU - Corsetti, M. T.
AU - Frassoni, F.
AU - Vassallo, F.
PY - 1998
Y1 - 1998
N2 - The quality of the graft is thought to be essential for a good outcome in aulologuus stem cell transplant for CML. We have recently demonstrated that a) Ph-negative peripheral blood progenitor cells (PBPC) can be collected by leukapheresis during early recovery after chemotherapy-induced marrow aplasia, b) these cells are able to restore nORnal polyclonal hemopoiesis after autografting and c) the best clinical results are achieved in patients autografted with Ph-negative PBPC In order to monitor minimal residual disease in Ph-negative PBPC, we set a quantitative-competitive RT-PCR assay for BCR-ABL and analyzed Ph-negative collections in 18 patients mobilized in the first year from diagnosis without previous IFN-a treatment. We generated a construct m which the fusion region of the BCR-ABL gene was cloned in pCR-II vector and a 222 bp of foreign DNA was inserted in the ABL portion of the cDNA. This construct was used as competitor DNA to estimate BCR-ABL and ABL transcripts in 147 samples Ratio between the t\u> BCR-ABL and ABL was calculated for every sample. Statistical correlation between cytogenetics and QC-RT-PCR was higher than 0.8. Ph-negative collection from the same patients showed more than one log of difference in the amount of BCR-ABL transcripts, with the lower levels in the first two teukaphereses Sample BCR-ABL trans/ugRNA (median) BCR-ABL/ABL diagnosis 50000 0.3 1st leuk. 100 0.002 2nd leuk. 100 0.002 3rd leuk. 500 0.006 4th leuk 500 0.01 Sthleuk 1500 0.01 Indeed, the BCR-ABL level found in the first leukaphereses of these patients was lower than in the corresponding samples from a group of patients pre-treated for more than 12 months with IFN-α therapy. Patients mob BCR-ABL Irans/BCR-ABL/ABL agRNA fmedl in the 1 st leuk. (med) £12 mo. fromdx.inoINF 100 0.002 >12mo.IFN 1000 0.01 In conclusion, quantitative-competitive RT-PCR for BCR-ABL has been proven to be a powerful tool in monitoring leukemic contamination in PBPC collections. Follow-up data of patients autografted with low-contamination PBPCs are necessary to establish the clinical relevance of this selection.
AB - The quality of the graft is thought to be essential for a good outcome in aulologuus stem cell transplant for CML. We have recently demonstrated that a) Ph-negative peripheral blood progenitor cells (PBPC) can be collected by leukapheresis during early recovery after chemotherapy-induced marrow aplasia, b) these cells are able to restore nORnal polyclonal hemopoiesis after autografting and c) the best clinical results are achieved in patients autografted with Ph-negative PBPC In order to monitor minimal residual disease in Ph-negative PBPC, we set a quantitative-competitive RT-PCR assay for BCR-ABL and analyzed Ph-negative collections in 18 patients mobilized in the first year from diagnosis without previous IFN-a treatment. We generated a construct m which the fusion region of the BCR-ABL gene was cloned in pCR-II vector and a 222 bp of foreign DNA was inserted in the ABL portion of the cDNA. This construct was used as competitor DNA to estimate BCR-ABL and ABL transcripts in 147 samples Ratio between the t\u> BCR-ABL and ABL was calculated for every sample. Statistical correlation between cytogenetics and QC-RT-PCR was higher than 0.8. Ph-negative collection from the same patients showed more than one log of difference in the amount of BCR-ABL transcripts, with the lower levels in the first two teukaphereses Sample BCR-ABL trans/ugRNA (median) BCR-ABL/ABL diagnosis 50000 0.3 1st leuk. 100 0.002 2nd leuk. 100 0.002 3rd leuk. 500 0.006 4th leuk 500 0.01 Sthleuk 1500 0.01 Indeed, the BCR-ABL level found in the first leukaphereses of these patients was lower than in the corresponding samples from a group of patients pre-treated for more than 12 months with IFN-α therapy. Patients mob BCR-ABL Irans/BCR-ABL/ABL agRNA fmedl in the 1 st leuk. (med) £12 mo. fromdx.inoINF 100 0.002 >12mo.IFN 1000 0.01 In conclusion, quantitative-competitive RT-PCR for BCR-ABL has been proven to be a powerful tool in monitoring leukemic contamination in PBPC collections. Follow-up data of patients autografted with low-contamination PBPCs are necessary to establish the clinical relevance of this selection.
UR - http://www.scopus.com/inward/record.url?scp=33748602916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748602916&partnerID=8YFLogxK
M3 - Article
VL - 26
SP - 758
JO - Experimental Hematology
JF - Experimental Hematology
SN - 0301-472X
IS - 8
ER -